Current pharmacotherapy of idiopathic intestinal inflammations can benefit from standard (conventional) therapies based on results of controlled studies, non-standard (unconventional) therapies based on pilot and uncontrolled studies, or can be a subject of clinical experiments. Clinical experimental area is a way to a progress in traditional treatment methods. Currently it includes a group of new drugs (immunosuppressives tacrolimus mycophenolate, thalidomide, biologic therapy, probiotics, neuroinflammation blockers), new treatment techniques (cytaphereses, sequential immunosuppression, immunosuppression with high doses), and finally new indications (chemoprophylaxis).